(Total Views: 441)
Posted On: 10/14/2020 10:59:07 AM
Post# of 7503
![Avatar](https://investorshangout.com/images/ProfileImages/2010907820_59156_swordfish.jpg)
Goals being met by BIEL 2.0 .....
2. We also have a signed agreement with a commercial firm that is in the process of recruiting and training up to 400 independent sales representatives who will actively sell our RecoveryRx postoperative pain product line into doctors’ offices, wound clinics, nursing facilities, and hospitals. As with the three OTC retail-oriented companies mentioned above, we will act as the original equipment manufacturer (OEM) for this sales force, providing them with devices upon receiving purchase orders. The principles of this sales force anticipate that sales will begin in Q4 of 2020 and ramp up over the next calendar year.
Q4 has just begun and there are 150 Sales Reps, Trained by BIEL, in the field selling RecoveryRx to doctors’ offices, wound clinics, nursing facilities, and hospitals.
Goals in the Pipeline.....
1. We now have signed long term contracts with, and received initial stocking orders and cash deposits from, three major companies. These initial orders total more than 120,000 ActiPatch devices. These three companies will be selling our devices into the United States over-the-counter (OTC) consumer health retail market. They will differentiate their offerings by utilizing different retail channels, branding strategies, and attachment systems (to affix the device on to various locations on the body). Their retail launch dates vary but are currently scheduled between Q4 of 2020 and Q2 of 2021 , reflecting industry practice for retailers to plan launch times six to nine months into the future.
3. In terms of international sales, we recently signed a licensing agreement with a major international company and are in the final stages of signing an agreement with another large international company. Both of these companies need to register our products with their respective local medical regulatory authorities before they can distribute and sell our products .
In addition, the sales force of our long-standing distributor, Mundipharma, has reentered the field after a slow down of sales activity due to the pandemic. Based in part on this new activity, they are forecasting a reorder in Q4 of 2020.
4. Our engineering and clinical team has continued to improve our understanding of the mechanism of action for the technology behind our devices and to develop new versions of our products. In addition, in conjunction with some of our new sales representatives, we are in the process of establishing new clinical alliances to further strengthen the clinical evidence on our devices.
https://www.globenewswire.com/news-release/20...mpany.html
2. We also have a signed agreement with a commercial firm that is in the process of recruiting and training up to 400 independent sales representatives who will actively sell our RecoveryRx postoperative pain product line into doctors’ offices, wound clinics, nursing facilities, and hospitals. As with the three OTC retail-oriented companies mentioned above, we will act as the original equipment manufacturer (OEM) for this sales force, providing them with devices upon receiving purchase orders. The principles of this sales force anticipate that sales will begin in Q4 of 2020 and ramp up over the next calendar year.
Q4 has just begun and there are 150 Sales Reps, Trained by BIEL, in the field selling RecoveryRx to doctors’ offices, wound clinics, nursing facilities, and hospitals.
Goals in the Pipeline.....
1. We now have signed long term contracts with, and received initial stocking orders and cash deposits from, three major companies. These initial orders total more than 120,000 ActiPatch devices. These three companies will be selling our devices into the United States over-the-counter (OTC) consumer health retail market. They will differentiate their offerings by utilizing different retail channels, branding strategies, and attachment systems (to affix the device on to various locations on the body). Their retail launch dates vary but are currently scheduled between Q4 of 2020 and Q2 of 2021 , reflecting industry practice for retailers to plan launch times six to nine months into the future.
3. In terms of international sales, we recently signed a licensing agreement with a major international company and are in the final stages of signing an agreement with another large international company. Both of these companies need to register our products with their respective local medical regulatory authorities before they can distribute and sell our products .
In addition, the sales force of our long-standing distributor, Mundipharma, has reentered the field after a slow down of sales activity due to the pandemic. Based in part on this new activity, they are forecasting a reorder in Q4 of 2020.
4. Our engineering and clinical team has continued to improve our understanding of the mechanism of action for the technology behind our devices and to develop new versions of our products. In addition, in conjunction with some of our new sales representatives, we are in the process of establishing new clinical alliances to further strengthen the clinical evidence on our devices.
https://www.globenewswire.com/news-release/20...mpany.html
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)